Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.

OA: closed
📄 Open PDF View on PubMed View at publisher
AI-generated summary by claude@2026-08, 2026-08-04

A GnRH antagonist protocol supplemented with low-dose hCG showed improved oocyte maturation and embryo quality compared to agonist protocols, with a trend towards lower OHSS.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PurposeTo examine the efficacy of low-dose hCG using a GnRH antagonist protocol.MethodsProspective randomized study was performed at the Kyono Ladies Clinic. One hundred ninety-two women (<40 -years old, <3 previous cycles) were randomly assigned to GnRH agonist (buserelin) long protocol (LP, n = 66), GnRH antagonist (cetrorelix) with no low-dose hCG protocol (NhCGP, n = 63), or GnRH antagonist with low-dose hCG protocol (hCGP, n = 63).ResultsThe hCGP was associated with reduced total amounts of FSH, increased oocyte maturation rate, high-quality day 3 embryos rate, and number of frozen embryos. Ovarian hyperstimulation syndrome (OHSS) tended to be lower in the GnRH antagonist protocol. Pregnancy and implantation rates did not differ significantly between study groups.ConclusionsDaily low-dose hCG supplementation in the late follicular phase could improve the outcome in FSH based-GnRH antagonist protocol. This protocol, however, does require further modifications, including determination of the optimal doses for hCG and gonadotropin pretreatment.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-09T06:10:49.860119+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00